Anticoagulants

Gusto IIb/Hirudin Provides Advantage Over Heparin as Blood Thinner

Published in Blood Weekly, September 30th, 1996

Patients with acute coronary syndromes who were given the anticoagulant hirudin were less likely to incur a heart attack or death than a similar group of patients who were treated with heparin.

The finding is among the results of the second Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (Gusto IIb) study published in the September 12, 1996, issue of the New England Journal of Medicine.

The 12,142-patient study compared heparin, the intravenous anticoagulant routinely used today, with hirudin, a genetically engineered compound that is not yet commercially available. Hirudin is a protein derived from leech saliva, the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1996-09-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry